Published in J Natl Cancer Inst on January 19, 2005
OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL) (OPTIMAL) | NCT02335957
Intensity Modulated Radiotherapy for Breast Cancer (IMRT) | NCT00594477
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys (2014) 1.61
Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys (2010) 1.40
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med (2013) 1.35
Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol (2010) 1.19
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer. J Clin Oncol (2010) 1.12
Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat (2012) 1.10
Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data. Int J Hyperthermia (2010) 1.08
Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control. Int J Radiat Oncol Biol Phys (2009) 1.04
Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res (2012) 1.02
Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg (2007) 1.00
An Eighteen-Gene Classifier Predicts Locoregional Recurrence in Post-Mastectomy Breast Cancer Patients. EBioMedicine (2016) 0.96
Wide tangential fields including the internal mammary lymph nodes in patients with left-sided breast cancer. Influence of respiratory-controlled radiotherapy (4D-CT) on cardiac exposure. Strahlenther Onkol (2009) 0.96
Post mastectomy linac IMRT irradiation of chest wall and regional nodes: dosimetry data and acute toxicities. Radiat Oncol (2013) 0.96
Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: is there a role for radiation therapy? Radiat Oncol (2011) 0.95
Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes. Br J Cancer (2013) 0.94
Short-term displacement and reproducibility of the breast and nodal targets under active breathing control. Int J Radiat Oncol Biol Phys (2007) 0.93
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol (2010) 0.92
Late Toxicity of Radiotherapy: A Problem or a Challenge for the Radiation Oncologist? Breast Care (Basel) (2011) 0.92
Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in left-sided breast irradiation for patients with early-stage or locally advanced breast cancer. Am J Clin Oncol (2013) 0.91
Postmastectomy radiation therapy: an overview for the practicing surgeon. ISRN Surg (2013) 0.91
Younger age as a prognostic indicator in breast cancer: a cohort study. BMC Cancer (2011) 0.91
Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy. Radiat Oncol (2013) 0.90
ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res (2012) 0.89
Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2011) 0.89
Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Radiol Oncol (2014) 0.88
Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis? Cancer Res Treat (2013) 0.87
Muscle-sparing TRAM flap does not protect breast reconstruction from postmastectomy radiation damage compared with the DIEP flap. Plast Reconstr Surg (2014) 0.87
Nanotechnology in radiation oncology. J Clin Oncol (2014) 0.86
Radiation impact in breast cancer. Breast Cancer Res (2009) 0.86
Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients. World J Surg Oncol (2010) 0.86
Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation. Radiother Oncol (2010) 0.86
Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist (2013) 0.86
Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery. Radiat Oncol (2013) 0.85
Cardiac effects of anticancer therapy in the elderly. J Clin Oncol (2014) 0.84
Breast conserving surgery versus mastectomy: the influence of comorbidities on choice of surgical operation in the Department of Defense health care system. Am J Surg (2013) 0.84
Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy - a retrospective analysis. BMC Cancer (2008) 0.84
Post-mastectomy radiotherapy for breast cancer patients with t1-t2 and 1-3 positive lymph nodes: a meta-analysis. PLoS One (2013) 0.83
Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys (2007) 0.83
Should Postmastectomy Radiotherapy to the Chest Wall and Regional Lymph Nodes Be Standard for Patients with 1-3 Positive Lymph Nodes? Breast Care (Basel) (2011) 0.83
Options in breast cancer local therapy: who gets what? World J Surg (2012) 0.83
Meta-analysis of incidence of early lung toxicity in 3-dimensional conformal irradiation of breast carcinomas. Radiat Oncol (2013) 0.83
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div (2013) 0.83
Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol (2013) 0.83
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys (2008) 0.83
Evaluation of multiple breathing states using a multiple instance geometry approximation (MIGA) in inverse-planned optimization for locoregional breast treatment. Int J Radiat Oncol Biol Phys (2008) 0.83
Patterns of Pelvic Radiotherapy in Patients with Stage II/III Rectal Cancer. J Cancer Epidemiol (2013) 0.82
The effects of ECE on the benefits of PMRT for breast cancer patients with positive axillary nodes. J Radiat Res (2013) 0.82
Guidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8(th) Annual Women's Cancer Initiative - Tata Memorial Hospital (WCI-TMH) Conference. Indian J Med Paediatr Oncol (2012) 0.82
The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS One (2013) 0.81
A pilot randomized clinical study of the additive treatment effect of photodynamic therapy in breast cancer patients with chest wall recurrence. J Breast Cancer (2014) 0.81
In vivo surface dose measurement using GafChromic film dosimetry in breast cancer radiotherapy: comparison of 7-field IMRT, tangential IMRT and tangential 3D-CRT. Radiat Oncol (2014) 0.81
Benefits, risks, and safety of external beam radiation therapy for breast cancer. Int J Womens Health (2015) 0.81
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat (2010) 0.81
A novel technique for post-mastectomy breast irradiation utilising non-coplanar intensity-modulated radiation therapy. Br J Radiol (2010) 0.81
Dose to level I and II axillary lymph nodes and lung by tangential field radiation in patients undergoing postmastectomy radiation with tissue expander reconstruction. Radiat Oncol (2011) 0.80
Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer. J Breast Cancer (2013) 0.80
Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol (2009) 0.80
Radiation-induced impairment in lung lymphatic vasculature. Lymphat Res Biol (2014) 0.80
Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective? World J Surg (2011) 0.80
Malpractice suits and physician apologies in cancer care. J Oncol Pract (2011) 0.80
Radiation treatment in pathologic n0-n1 patients treated with neoadjuvant chemotherapy followed by surgery for locally advanced breast cancer. J Breast Cancer (2012) 0.79
More evidence that locoregional radiation therapy improves survival: what should we do? J Natl Cancer Inst (2005) 0.79
Use of thoracodorsal artery perforator flaps to enhance outcomes in alloplastic breast reconstruction. Plast Reconstr Surg Glob Open (2014) 0.79
Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no? Curr Oncol (2013) 0.79
Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys (2015) 0.78
Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era: A Retrospective Korean Breast Cancer Society Report. Medicine (Baltimore) (2016) 0.78
Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study. Oncotarget (2016) 0.78
Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes (2010) 0.78
Male breast cancer: 20-year survival data for post-mastectomy radiotherapy. Breast Care (Basel) (2013) 0.78
The application of PET-CT to post-mastectomy regional radiation therapy using a deformable image registration. Radiat Oncol (2013) 0.78
The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med (2011) 0.78
Siah1 proteins enhance radiosensitivity of human breast cancer cells. BMC Cancer (2010) 0.78
Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy. Breast Cancer (Dove Med Press) (2014) 0.78
Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1-3 positive lymph nodes: a retrospective study. J Radiat Res (2013) 0.78
Post-mastectomy radiotherapy can improve survival in breast cancer patients aged 35 years or younger with four or more positive nodes but not in one to three positive nodes. Ther Clin Risk Manag (2014) 0.77
Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes. Cancer Biol Med (2014) 0.77
Successful pregnancy after breast cancer therapy: dream or reality? Int Semin Surg Oncol (2009) 0.77
Prognostic value of the nodal ratio and ki-67 expression in breast cancer patients treated with postmastectomy radiotherapy. J Breast Cancer (2013) 0.77
In vitro models of cancer stem cells and clinical applications. BMC Cancer (2016) 0.77
Breast cancer (non-metastatic). BMJ Clin Evid (2011) 0.77
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. Ann Surg Oncol (2015) 0.77
Influence of the presence of tissue expanders on energy deposition for post-mastectomy radiotherapy. PLoS One (2013) 0.77
Radiation therapy in early-stage invasive breast cancer. Indian J Surg Oncol (2011) 0.77
Paclitaxel impairs adipose stem cell proliferation and differentiation. J Surg Res (2015) 0.77
Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer (Dove Med Press) (2015) 0.77
Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. J Radiat Res (2014) 0.76
A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women. J Clin Diagn Res (2015) 0.76
Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab. Oncotarget (2016) 0.76
The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer. Strahlenther Onkol (2009) 0.76
Re: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst (2005) 0.76
Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005. Cancer Med (2013) 0.76
Advances in managing breast cancer: a clinical update. F1000Prime Rep (2014) 0.76
Managing breast cancer in younger women: challenges and solutions. Breast Cancer (Dove Med Press) (2015) 0.76
Radiotherapy of the Lymphatic Pathways in Early Breast Cancer. Breast Care (Basel) (2015) 0.76
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Molecular characterisation of soft tissue tumours: a gene expression study. Lancet (2002) 7.05
Metastatic behavior of breast cancer subtypes. J Clin Oncol (2010) 6.17
Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol (2005) 4.99
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94
Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol (2005) 4.31
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
The Global Public Health Intelligence Network and early warning outbreak detection: a Canadian contribution to global public health. Can J Public Health (2006) 3.70
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol (2006) 3.42
Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol (2004) 3.33
Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med (2004) 3.21
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2012) 3.07
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer (2007) 2.84
Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol (2002) 2.75
Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet (2009) 2.73
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood (2005) 2.69
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2006) 2.38
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol (2003) 2.34
Increased risk of breast cancer associated with long-term shift work in Canada. Occup Environ Med (2013) 2.24
GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. Int J Cancer (2010) 2.18
Consensus conference on breast conservation. J Am Coll Surg (2006) 2.17
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Antidepressant use among survivors of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program. Pediatr Blood Cancer (2012) 2.11
Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev (2005) 2.10
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (2008) 2.09
Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys (2010) 2.08
Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol (2002) 2.04
Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol (2002) 2.04
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer (2008) 2.02
Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer (2008) 2.01
Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol (2008) 1.91
Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem (2005) 1.86
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics. Pediatr Blood Cancer (2010) 1.78
Intensive care unit admission has minimal impact on long-term mortality. Crit Care Med (2002) 1.73
Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.70
Risk of childhood leukemia associated with vaccination, infection, and medication use in childhood: the Cross-Canada Childhood Leukemia Study. Am J Epidemiol (2007) 1.65
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol (2004) 1.61
Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol (2010) 1.59
Impact of routine pathology review on treatment for node-negative breast cancer. J Clin Oncol (2012) 1.59
Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys (2007) 1.58
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Int J Radiat Oncol Biol Phys (2002) 1.50
Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Radiat Oncol Biol Phys (2007) 1.49
The problem of evidence-based medicine: directions for social science. Soc Sci Med (2004) 1.47
Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer (2005) 1.47
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol (2002) 1.47
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer (2005) 1.47
Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ (2004) 1.46
Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res (2009) 1.45
Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia. Lung Cancer (2004) 1.43
Multiple myeloma and occupational exposures: a population-based case-control study. J Occup Environ Med (2011) 1.43
Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada. Pediatr Blood Cancer (2007) 1.42
Does a three-field electron/minitangent photon technique offer dosimetric advantages to a multifield, photon-only technique for accelerated partial breast irradiation? Am J Clin Oncol (2010) 1.39
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer (2003) 1.38
Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.36
Target volume delineation for partial breast radiotherapy planning: clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys (2007) 1.34
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 1.27
Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol (2009) 1.25
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25
Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol (2005) 1.24
Predictors of supervised exercise adherence during breast cancer chemotherapy. Med Sci Sports Exerc (2008) 1.23
Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol (2003) 1.21
The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys (2007) 1.21
Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol (2012) 1.20
Reliability and validity testing of the Patient and Observer Scar Assessment Scale in evaluating linear scars after breast cancer surgery. Plast Reconstr Surg (2007) 1.19
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18
Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol (2003) 1.16
Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. Ann Behav Med (2008) 1.16
Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer (2008) 1.15